Compare SKYA & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYA | ELTX |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.7M | 63.3M |
| IPO Year | 2022 | 2014 |
| Metric | SKYA | ELTX |
|---|---|---|
| Price | $2.79 | $1.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | ★ 1.8M | 256.1K |
| Earning Date | 11-16-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | N/A | ★ N/A |
| Revenue | $204,120.00 | ★ $2,301,000.00 |
| Revenue This Year | $35,369.33 | N/A |
| Revenue Next Year | $9.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.91 | $1.47 |
| 52 Week High | $2.83 | $16.00 |
| Indicator | SKYA | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 75.68 | 20.20 |
| Support Level | $1.60 | N/A |
| Resistance Level | N/A | $1.97 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 98.37 | 0.00 |
SkyAI Inc is developing financial technology platforms focused on users in emerging markets. Its operations include the use of stablecoin-based payment infrastructure and artificial intelligence (AI) technologies to provide financial access, educational tools, and data analysis services for users in Asia, Latin America, and Africa. The company's platform will utilize the Solana blockchain network to support digital asset and on-chain data applications.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.